Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327539 | 0.89 | ALDH1A1 (0.64) | LMNAALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL24849235 | 0.87 | ALDH1A1 (0.51) | LMNASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL10357173 | 0.86 | LMNA (0.61) | LMNASMN1; SMN2ALDH1A1HTTKDM4E | |
| Pyrrocaine SCHEMBL25718 | 0.86 | MEN1 (0.70) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2096761 | 0.85 | MEN1 (0.73) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| Pyrrocaine SCHEMBL10757216 | 0.85 | MEN1 (0.68) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL22407740 | 0.85 | MEN1 (0.73) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| Pincainide SCHEMBL2110148 | 0.85 | MEN1 (0.73) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL24849177 | 0.84 | MEN1 (0.59) | LMNASMN1; SMN2ALDH1A1KDM4EHPGD | |
| Pyrrocaine SCHEMBL1651381 | 0.84 | MEN1 (0.67) | LMNAALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | claimed |
| WO-2023274258-A1 | HETEROATOM-SUBSTITUTED AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学华西医院 | 2023-01-05 | — | — | WO | disclosed |
| WO-2020156359-A1 | QUATERNARY AMMONIUM SALT COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学华西医院 | 2020-08-06 | — | — | WO | disclosed |
| US-8163803-B2 | less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance | Fundação Oswaldo Cruz—FIOCRUZ (BR) | 2012-04-24 | — | — | US | disclosed |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | disclosed |
| WO-2005025498-A2 | SUBSTITUTED ACETANILIDES AND BENZAMIDES FOR THE TREATMENT OF ASTHMA AND PULMONARY INFLAMMATION | CORUS PHARMA (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | LTA, LCT, LTC4S | LMNA 99/4885SMN1; SMN2 1477/4885ALDH1A1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.